SCINTIX® biology-guided radiotherapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.
When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our X1 platform uses to manage motion and treat solid tumors of any stage disease.
Learn About Emissions
Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.
Learn About Targeting
Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.
Discover the Potential
Treating cancer isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.
Learn About Treatment
By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.
Discover SCINTIX therapy.
See how SCINTIX therapy can play a role
in your cancer program.
Hackensack Meridian John Theurer Cancer Center initiates new clinical study HAYWARD, Calif., Jan. 8, 2025 – RefleXion® Medical, an external-beam theranostic oncology company, today announced initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX® biology-guided radiotherapy at Hackensack Meridian John Theurer Cancer Center, a research partner with Georgetown’s Lombardi Comprehensive Cancer Center, an NCI-designated […]
In a landscape of declining Medicare reimbursements for conventional radiotherapy over the past decade, SCINTIX® therapy stands alone as a new modality in radiation therapy that bucks the trend. In January 2024, SCINTIX therapy was granted accretive reimbursement compared to other radiotherapy modalities. The Centers for Medicare and Medicaid Services (CMS) established a national payment […]
Let us tell you more.
Contact UsStay up to date.
Sign Up